Shanghai North Carolina passed the "Little Giant" annual acceptance
Release time:
2020-08-14
Shanghai North Carolina Passed "Little Giant" Annual Acceptance
News Recently, Shanghai North Carolina Pharmaceutical Technology Co., Ltd., a new member of Jianfeng Pharmaceutical Co., Ltd., successfully passed the annual acceptance of Shanghai Science and Technology "Little Giant" Cultivation Enterprise.
In order to promote the independent innovation of enterprises, improve the core competitiveness of enterprises, enhance the competitive advantages of enterprises in domestic and foreign industries, and accelerate the construction of scientific and technological innovation, Shanghai North Carolina 2016 declared the Shanghai "Science and Technology Innovation Action Plan" science and technology "Little Giant" cultivation project and was approved, becoming a member of Shanghai's 87 "Little Giant" cultivation enterprises in that year, the project execution period is 2 years.
During the period of the Little Giant Cultivation Project, North Carolina completed the re-identification of Shanghai High-tech Enterprises and the identification of Songjiang District Enterprise Technology Center. Songjiang District Enterprise Technology Center was evaluated as excellent, passed the certification of Shanghai Academician Expert Workstation, passed the acceptance of Shanghai Patent Work Pilot Enterprises, and obtained a total of 4 invention patents authorized and 12 invention patents applied, registered trademarks 2 items, formulated enterprise standards 4 items, product testing reports 22 items, 2017 Songjiang District Industry-University-Research Innovation Project was approved and the project target was completed. Tinib drugs and their intermediates of
non-small cell lung cancer (NSCLC ) are the dominant varieties in North Carolina. In order to improve the existing tinib product line and consolidate the economic benefits and market share of this kind of products, North Carolina has carried out research and development on the latest generation of precision medicine special effect drugs such as cabozantinib (Cabozantinib) , ceritinib (Ceritinib ) and other kinds of API intermediates for tinib star varieties which are hot spots in the clinical research and development of generic drugs, also focus on the development of palbociclib (Palbociclib ) and gefitinib and other varieties of intermediate production process industrialization pilot and scale-up, and in-depth quality research and factory industrialization practice. In addition, North Carolina has also vigorously expanded the industrialization of the anti-diabetic drug pioglitazone, as well as the development of other products such as the endogenous active substance Paricalcitol, and carried out product layout for future development.
During the cultivation project period, North Carolina completed various tasks such as the optimization and construction of the innovation environment, the construction of the research and development team, and the research and development of scientific research projects, and carried out the upgrading and transformation of the research and development laboratory and pilot test platform, EIA filing and supporting environmental protection treatment facilities. 3# In mid-June, the Shanghai Municipal Science and Technology Commission launched the acceptance and evaluation of Shanghai's "Little Giant" enterprises. 12 enterprises recommended by the Songjiang District Science and Technology Commission participated in the defense. Kang Litao, general manager of Shanghai North Carolina, Li Qian, deputy general manager, and heads of R & D, finance and other departments participated in the on-site defense and successfully passed the defense acceptance. (Yang Shiqiong)
More information
Company fully deploys 2019 work
On January 28, the group company held a business analysis meeting to review and summarize the work situation in 2018, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises made reports on the overall work situation in 2018, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2019. Xiang Chongping, deputy general manager of the group company, made a systematic review of the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the internal control, safety and environmental protection work in 2018. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2018 and made a comparative analysis of the main economic indicators of each industrial sector. In 2018, the operating indicators of the company's various industrial sectors have improved significantly year-on-year, and the group company has also created the best operating performance in history. All units have completed the formulation of the second round of "three-year business plan", which points out the direction for the next three years of business work; the group company has also completed the first draft of the new "five-year strategic development plan", which is being revised and enriched. In addition, the two main businesses have also made substantial progress in investment expansion and industrial integration around strategic objectives, and the operating costs of major enterprises have decreased to varying degrees; the optimization of organizational structure and post setting has achieved new results, and management efficiency and people
2020
07-22
Company fully deploys 2019 work
On January 28, the group company held a business analysis meeting to review and summarize the work situation in 2018, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises made reports on the overall work situation in 2018, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2019. Xiang Chongping, deputy general manager of the group company, made a systematic review of the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the internal control, safety and environmental protection work in 2018. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2018 and made a comparative analysis of the main economic indicators of each industrial sector. In 2018, the operating indicators of the company's various industrial sectors have improved significantly year-on-year, and the group company has also created the best operating performance in history. All units have completed the formulation of the second round of "three-year business plan", which points out the direction for the next three years of business work; the group company has also completed the first draft of the new "five-year strategic development plan", which is being revised and enriched. In addition, the two main businesses have also made substantial progress in investment expansion and industrial integration around strategic objectives, and the operating costs of major enterprises have decreased to varying degrees; the optimization of organizational structure and post setting has achieved new results, and management efficiency and people
2020
07-31
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-31
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-30
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-31
Chairman Jiang Xiaomeng Directs Work in Yunnan Peak
On December 16, Jiang Xiaomeng, Secretary of the Party committee and chairman of the group company, went to Yunnan Jianfeng cement company to investigate and guide the work. On the morning of the same day, accompanied by the Yunnan peak management team, Jiang Xiaomeng went deep into the front line and successively went to the central control room of the production and manufacturing department, the raw material clay yard, the lignite yard and other areas for field investigation and investigation to understand the problems existing in the production and operation process. Subsequently, a business analysis meeting was held to make a comparative analysis of the various business indicators of Yunnan Jianfeng from January to November this year, and put forward two requirements to the management team: further strengthen internal management and improve execution; strengthen the coordination of external relations, and improve The ability and level of enterprise resource acquisition. At the Yunnan Jianfeng middle-level cadre meeting held on the afternoon of the 16th, Jiang Xiaomeng first fully affirmed Yunnan Jianfeng's highest output and best benefits since it was put into production in 2018, and expressed his gratitude to all cadres and employees of Yunnan Jianfeng for their hard work. After that, Jiang Xiaomeng made a detailed analysis of the cement industry and the regional market environment in Yunnan, and combined with the current production and operation situation of Yunnan Jianfeng, put forward the focus of the next step: 1. should fully attach importance to and mobilize the initiative and responsibility of employees at all levels to improve the overall execution of the team; 2. raw material mines are an important factor restricting the future development of cement enterprises, which should be paid full attention to and formulate clear strategies and methods, set out a timetable to obtain future production resources as much as possible; 3. continuously advocate and promote technological innovation, keep pace with the times, continuously improve production management, equipment management, production technology level, and maintain the competitive advantage of the industry; 4. further strengthen production
2020
07-31